Abstract | OBJECTIVE: To evaluate the safety and efficacy of hyperosmolar glucose injection in select unruptured tubal gestations with hCG levels less than 2500 mIU/mL. METHODS: In this prospective series, 16 patients with an hCG titer less than 2500 mIU/mL and an unruptured ectopic pregnancy were treated by tubal injection with hyperosmolar (50%) glucose. Hyperosmolar glucose was injected transabdominally into the antimesenteric site of the tubal pregnancy, using a 20-gauge spinal needle. The main outcome measures evaluated were duration of surgery, success rate, time to resolution, and follow-up tubal patency rates. RESULTS: Ninety-four percent (15) of the subjects were treated successfully with a median time to resolution of 24 days (range 5-78). The one treatment failure required methotrexate because of rising hCG titers and worsening pain 4 days after the patient was treated with hyperosmolar glucose. The mean (+/- standard error) duration of surgery was 45 +/- 6 minutes. So far, all ten patients undergoing postoperative hysterosalpingograms have demonstrated tubal patency in the treated tube. CONCLUSION: Laparoscopic injection with hyperosmolar glucose is an effective, systemically nontoxic alternative treatment for select unruptured ectopic pregnancies (hCG less than 2500 mIU/mL) that achieves tubal patency rates comparable to other conservative medical and surgical treatments.
|
Authors | T R Yeko, J C Mayer, A K Parsons, G B Maroulis |
Journal | Obstetrics and gynecology
(Obstet Gynecol)
Vol. 85
Issue 2
Pg. 265-8
(Feb 1995)
ISSN: 0029-7844 [Print] United States |
PMID | 7824243
(Publication Type: Journal Article)
|
Chemical References |
- Chorionic Gonadotropin
- Glucose
- Methotrexate
|
Topics |
- Chorionic Gonadotropin
(blood)
- Fallopian Tube Patency Tests
- Female
- Glucose
(administration & dosage)
- Humans
- Injections
- Laparoscopy
- Methotrexate
(therapeutic use)
- Osmolar Concentration
- Pregnancy
- Pregnancy, Tubal
(blood, therapy)
- Prospective Studies
|